A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples.

We describe a method for the immunocytochemical assessment of estrogen receptor (ER) status on routinely processed, formalin-fixed tissue using a recently developed commercially available monoclonal antibody (Dako 1D5) with a microwave antigen retrieval technique. A series of 90 cases of human breast carcinoma was analyzed and the staining was assessed using a semiquantitative microscopic scoring method and by assessment of the percentage of nuclei showing positive staining. The results were compared with assessment using another commercially available antibody (Abbott H222) and with clinical response to tamoxifen therapy. Direct comparison of the paired sets of H scores and the percentage of positively stained nuclei using the two different techniques showed a significant correlation. By assigning an arbitrary cut-off for positivity of H score = 50, assessment of ER status using DAKO 1D5 antibody was found to correlate with response to tamoxifen therapy with a sensitivity of 90% and a specificity of 51%, similar to values in previous studies using other methods. We conclude that assessment of ER status using this new antibody and technique gives accurate results on routinely processed, formalin-fixed tissue and may be used as an alternative to other methods.

[1]  A. Forrest,et al.  Prognostic significance of oestrogen and progestogen receptor activities in breast cancer , 1987, The British journal of surgery.

[2]  C. Elston,et al.  Methodology of immunohistological detection of oestrogen receptor in human breast carcinoma in formalin‐fixed, paraffin‐embedded tissue: a comparison with frozen section methodology , 1993, Histopathology.

[3]  A. Bateman,et al.  immunocytochemistry: a study of 80 antibodies , 2022 .

[4]  U. Chetty,et al.  The cytochemical detection of oestrogen receptors in fine needle aspirates of breast cancer; correlation with biochemical assay and prediction of response to endocrine therapy. , 1988, British Journal of Cancer.

[5]  I. Ellis,et al.  Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases. , 1987, British Journal of Cancer.

[6]  R. Blamey,et al.  Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer. , 1992, British Journal of Cancer.

[7]  R. Hawkins,et al.  The differing predictive values of oestrogen receptor assays for large breast cancers. , 1992, Postgraduate medical journal.

[8]  G. Greene,et al.  Immunostaining of Estrogen Receptor in Paraffin Sections of Breast Carcinomas Using Monoclonal Antibody D75P3U03B3: Effects of Fixation , 1987, The American journal of surgical pathology.

[9]  B. Reid,et al.  Oestrogen receptor in breast cancer: prognostic studies using a new immunohistochemical assay , 1990, Histopathology.

[10]  M. Key,et al.  Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. , 1991, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[11]  A. C. Carter,et al.  Immunohistologic localization of estrogen receptors in breast cancer with monoclonal antibodies. Correlation with biochemistry and clinical endocrine response , 1985, Cancer.

[12]  D. Kiang,et al.  Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. , 1978, The New England journal of medicine.

[13]  Chiu Ky Use of microwaves for rapid immunoperoxidase staining of paraffin sections. , 1987 .

[14]  G. Greene,et al.  Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells , 1984, Nature.

[15]  W. McGuire,et al.  Abnormal estrogen receptor in clinical breast cancer , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[16]  R C Coombes,et al.  Immunocytochemical assay for estrogen receptor in patients with breast cancer: relationship to a biochemical assay and to outcome of therapy. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Jensen,et al.  Human breast cancer: Heterogeneity of estrogen binding sites , 1981, Cancer.

[18]  T. Anderson,et al.  Assessment of oestrogen receptor content of breast carcinoma by immunohistochemical techniques on fixed and frozen tissue and by biochemical ligand binding assay. , 1990, Journal of clinical pathology.

[19]  E B Cox,et al.  Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. , 1985, Archives of pathology & laboratory medicine.

[20]  K. Walker,et al.  Influence of the antioestrogen tamoxifen on normal breast tissue. , 1991, British Journal of Cancer.